Research

**The role of GSTM1 gene polymorphisms in lung cancer development in Turkish population**
Adalet Demir*, Sedat Altin, Davut Pehlivan, Mulahim Demir, Fatih Yakar, Ekrem Cengiz Seyhan and Seyyit Ibrahim Dincer

Address: 1Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Department of Thoracic Surgery, Istanbul, Turkey, 2Istanbul University, Istanbul Medical Faculty, Department of Medical Genetics, Istanbul, Turkey and 3Istanbul University, Istanbul Medical Faculty, Department of Chest Diseases, Istanbul, Turkey

Email: Adalet Demir* - dradalet@hotmail.com; Sedat Altin - sedataltin@yahoo.com; Davut Pehlivan - davutpehliyan@yahoo.com; Mulahim Demir - mulahimdemir@hotmail.com; Fatih Yakar - fyakar@yahoo.com; Ekrem Cengiz Seyhan - drekremcs@yahoo.com; Seyyit Ibrahim Dincer - sibrahimdincer@yahoo.com

* Corresponding author

**Abstract**

**Background:** Glutathione S-transferase (GSTs) plays an important role in the detoxification of many xenobiotics involved in the etiology of cancer. In different ethnic groups, variations in null allele frequency have been observed. We have investigated GSTM1 gene polymorphisms in healthy subjects and lung cancer patients in the Turkish population and reviewed the control subjects of the studies performed in the Turkish population.

**Methods:** Following blood sampling from patients and controls, DNA samples were extracted from the whole blood and were amplified by using polymerase chain reaction (PCR) method in all of the 256 cases, consisting of 102 previously diagnosed with lung cancer and 154 healthy controls.

**Results:** The prevalence of GSTM1-null genotype in the lung cancer patients was 49%, compared to 52.6% in the control group (OR = 1.39, 95% CI = 0.70–1.90, p = 0.57). There were also no significant relationships in GSTM1 genotypes among histopathologic types of lung cancers (p > 0.05). The frequency of GSTM1 was found to be 41.2% (n = 1809) when the control subjects of the studies performed in Turkish population were reviewed.

**Conclusion:** We have observed that GSTM1 genotype is not an independent risk factor for lung cancer.

1. **Background**

Carcinoma of the lung is the most common cancer and the most frequent cause of death in the patients with cancer around the world [1]. Environmental carcinogens such as active and passive smoking, air pollution and environmental exposures have strong influences on individual factors [2]. In humans, there are several genetic polymorphisms of the enzymes involved in metabolic activation and detoxification of pulmonary carcinogens including polycyclic aromatic hydrocarbons (PAH) and aromatic amines. Interindividual differences in ability to activate and detoxify carcinogens are expected to affect the risk of developing lung cancer [3]. Polymorphisms of the genes encoding phase I and phase II xenobiotic metabolizing enzymes were found to be associated with the risk of developing lung cancer.
enzymes have been shown to be associated with susceptibility to lung cancer in a number of epidemiologic studies [4]. However, most of these studies are limited by lack of adequate statistical power. To overcome this limitation, the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogens (GSEC) has begun and is on-going to pool raw data of studies on metabolic genetic polymorphisms and cancer risk [5].

Glutathione S-transferase (GSTs) plays an important role in cellular defense mechanism since they are involved in detoxification of many carcinogens and environmental pollutants and facilitate their excretion and also have a role in protection against oxidative stress [6,7]. The frequencies of polymorphic genes in control populations have been reported to be different in various ethnic groups. In addition, interethnic differences have been established [7-9]. GSTM1 deletion frequencies range from 42% to 60% in Caucasians [8].

Some studies suggest that the GSTM1 null genotype confers an increased risk of lung cancer but this result has not been approved by others, especially recent meta and pooled analysis [5,7,10-13].

The aims of the present study are to evaluate the frequencies of GSTM1 gene polymorphisms in Turkish population and whether genetic polymorphisms in GSTM1 influence individual susceptibility to lung cancer in Turkish population or not.

2. Methods
2.1. Study subjects and sample collection
A total 256 subjects, composed of 102 lung cancer patients, who were admitted to Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery in Istanbul between 2001–2005, and 154 healthy controls were included in this study. All cancer patients and controls were born in Turkey. The control group had neither cancers nor chronic diseases. The mean ages were found to be 56.3 ± 10 (range 30–75) and 35.1 ± 11 (range 20–65) in cancer group and healthy controls, respectively. Ninety-four patients in cancer group and 110 subjects in healthy controls were smokers. This study was approved by local hospital ethics committee on human research. All patients gave informed consent.

2.2. GSTM1 genotyping
DNA samples were amplified with the primers: 5'-GAACTCCCTGAAAAGCTAAAGC -3' and 5'-GTTGGGCTAAAAATATACGGTGG-3' for GSTM1 which produced a 219 bp product [14]. The PCR amplification was carried out 1 µg DNA in 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 3 mM MgCl2, 0.3 mM deoxyribonucleotide triphosphates (Fermentas), 0.2 µM of each primer and 1.5 U of Taq polymerase (Fermentas) in a total volume of 50 µl. Amplification was performed with initial denaturation at 94°C for 5 minutes, followed by 30 cycles at 94°C for 1 minute, 61°C for 1 minute, and 72°C for 1 minute, and a final extension at 72°C for 10 minute, using a MJ Research PTC160 thermal cycler. The amplification product (10 µl) was visualized in an ethidium bromide stained 1.5% agarose gel. All the genotype determination were carried out twice in independent experiments and all the inconclusive samples were reanalyzed. The results are shown in figure 1.

2.3. Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences Program (SPSS, Version 10). Pearson’s X² test was used to examine differences with regard to demographic variables, smoking and distribution of genotypes. Associations between the GSTM1 polymorphisms and risk of lung cancer were estimated using odds ratios (ORs) and 95% confidence intervals (95% CIs) calculated by conditional logistic regression.

3. Results
The demographic characteristics of the cancer group and healthy controls are shown in the Table 1. The prevalence of GSTM1 (0/0) genotype in the cancer group was 49% compared to 52.6% in control group. But the difference was not statistically significant (OR = 1.39, 95% CI = 0.70–1.90, P = 0.55) (Table 2).

Histopathological evaluation, performed according to WHO criteria, revealed that epidermoid carcinoma, adenocarcinoma and the others types were present in 62.7% (n = 64), 24.5%(n = 25) and 12.7% (n = 13) out of 102 cancer group, respectively. There was no statistically significant difference among the histopathologic types of lung cancer (p > 0.05) and prevalence of GSTM1 polymorphism.

4. Discussion
There are a lot of epidemiological and genetical studies with the expectation to monitorize the risk of lung cancer using specific biomarkers. GST gene polymorphism is one of the subject of matter. A number of studies have been
tried to establish the relationship between polymorphic expression of different GSTs and lung cancer risk in different ethnic populations [7,10,15,16], and the results have been conflicting [15,17]. One reason for the discrepancies could be the fact that most studies were conducted in different populations (one of the discrepancies that we encountered is due to holding the study in different populations). However, none of the main characteristics of the subjects explain satisfactorily the apparent discrepancies (i.e. race, histological type and level of smoking). Different histological subtypes of lung cancer, in particular may also be related to respective exposures or factors, and thus need to be analyzed separately [15,18].

The M1 variant of GST (GSTM1) detoxifies reactive intermediates of PAHs and other carcinogens. Although, the relationship between GSTM 1 polymorphism and lung cancer has been studied by various investigators, the effect of GSTM 0/0 null allele has not been explained clearly yet. A significant association of GSTM1 null genotype with lung cancer has already been observed in two large studies belongs to Japanese [19,20] and two in Chinese [21,22]. Furthermore, a study in Caucasians reported a significant association between lung adenocarcinoma and the GSTM1 null genotype [23]. In a meta-analysis study by Mc. Williams et al., it was shown that GSTM 0/0 null allele was a risk factor for the development of the lung cancer [24]. A meta-analysis of 11 studies found an OR of 1.6 (95% CI = 1.26–2.04) for an association between the GSTM1-null genotype and lung cancer risk [25]. A meta-analysis published by Simone Benhamou and co-workers reported that there was no statistically significant relationship between carrying GSTM null genotype and susceptibility to lung cancer but the number of the patients carrying this genotype was higher in the lung cancer group [12]. Although Pinarbası et al. [26] reported a correlation between GTSM1 and lung cancer (p = 0.0001) in the Turkish population, the other trials conducted by Aras et al. [27] and Ozturk et al. [28] in Turkish population revealed the contrary (p > 0.05) (Table 4). In our study, we found no statistically significant relation between GSTM null genotype and susceptibility to lung cancer. Additionally, the rate of GSTM null genotype was higher in control group than cancer patients.

The frequencies of polymorphic genes in control populations have been reported to be different in various ethnic groups. In addition, intra-ethnic differences have been established [8,9]. GSTM1 frequencies range from 42 to 60% in Caucasians [8]. GSTM1 null genotype has been shown to be 31 to 66% in Asians, Indians and Caucasians [28-30]. On the other hand, GSTM1 deletion polymorphism for African-Americans was found to be 23–35% [31] and for Chileans was 21% [10]. In these series the frequency of GSTM1 null genotype was 52.6% which was similar to some European countries (Germany, Denmark, and France), Canada, and Korea (Table 4).

When the control groups of studies performed in Turkish population are reviewed, the frequency of GSTM1 null genotype was found to be 41.2% (n = 1809). This figure is lower than European countries, United States, Saudi Arabia, Japan, Singapore, and Korea (Table 4).

Several studies have also been carried out in this regard in Turkish populations. However, some need verification and others are contradictory. GSTM1 null genotype has been shown to be 18 to 66% in Turkish population (n = 1809) (Table 3). In Ozturk and co-workers study [28], GSTM1 null genotype incidence was found to be 49.2% in Turkish population. While Aktas et al. [27] found the prevalence of null polymorphism 34.7%; Pinarbasý et al. [26] detected it to be 18% in Turkish population. The reason for this difference between both studies was attributed to regional variation of the controls included in these

| Genotypes | Patients n (%) | Control n (%) | OR(95%) CI | p value |
|-----------|---------------|--------------|------------|---------|
| GSTT1     |               |              |            |         |
| Present   | 52(51%)       | 73(47.4%)    | 1.0        |         |
| Null      | 50(49%)       | 81(52.6%)    | 1.39(0.70–1.90) | 0.57   |

Abbreviations: OR, odds ratio; CI, confidence interval

Table 2: Frequency of GSTM1 genotypes in lung cancer patients and controls
studies by Pýnarbaş. While Pýnarbaş included only individuals from Central Anatolia region of Turkey, Aktas did not report such a restriction [26]. In the current series the frequency of GSTM1 genotype was found to be 52.6% and is the highest among the series in Turkish population except series of Aras. The possible explanation for the high rates of the current series and Aras’ series could be the inclusion of subject living in two large cities of Turkey, Istanbul and Ankara containing people from all over the country. In our previous study, there was no significant relationship between lung cancer and gene polymorphism and we had concluded that insignificance was due to subject number inadequacy [7] but as we have involved more subjects, we could not improve the significance.

In conclusion, we observed that carrying the GSTM1 genotype is not a risk factor for lung cancer, alone. The frequencies of GSTM1-null genotype in control Turkish populations have been observed to be intra-ethnic differences. In future, the risk of lung cancer is expected to be monitored using specific biomarkers in genetic researches.

Table 3: The frequency of GSTM1 null genotype in Turkish population

| Studies of Turkey | Genotypes       | Patients (n =) | Percentage | Healthy Controls (n =) | Percentage | OR(95%) CI  | p value |
|-------------------|-----------------|----------------|------------|------------------------|------------|-------------|---------|
| Pýnarbaş et al (2003) (26)* | GSTM1 null | 101 | 48% | 206 | 18% | 4.14(2.36–7.27) | p = 0.0001 |
| Aras et al. (ANK) (27)* | GSTM1 null | 54 | 72.7 | 100 | 66% | 0.73(0.33–1.59) | p > 0.05 |
| Öztürk et al. (2003) (28)* | GSTM1 null | 55 | 47.3% | 65 | 49.2% | p > 0.05 |
| Current series* | GSTM1 null | 102 | 49% | 154 | 52.6% | 1.397(0.70–1.90) | p = 0.57 |
| Ada et al. (2004) (9) | GSTM1 null | - | - | 133 | 51.9% | - | - |
| Özbek et al. (2001)(32) | GSTM1 null | - | - | 130 | 47% | - | - |
| Seyitoğlu et al. (2003) (33) | GSTM1 null | - | - | 200 | 47% | - | - |
| Aktas et al. (2001) (34) | GSTM1 null | - | - | 172 | 34.7% | - | - |
| Toruner et al. (2001) (35) | GSTM1 null | - | - | 121 | 45.5% | - | - |
| Tamer et al. (2004) (36) | GSTM1 null | - | - | 103 | 40.8% | - | - |
| Tursen et al. (2004) (37) | GSTM1 null | - | - | 178 | 24.2% | - | - |
| Tamer et al. (2004) (38) | GSTM1 null | - | - | 247 | 41.7% | - | - |
| Studies of Turkey(Total) | GSTM1 null | - | - | 1809 | 41.2% | - | - |

* Studies with lung cancer patients

Table 4: The frequency of GSTM1 null genotype in control populations, geographic distribution

| Studies (year) | Country         | Genotypes   | Healthy controls (n =) | Percentage |
|----------------|-----------------|-------------|------------------------|------------|
| Garte et al. (2001) | Denmark        | GSTM1 null | 537 | 53.6% |
| Garte et al. (2001) | Finland        | GSTM1 null | 482 | 46.9% |
| Garte et al. (2001) | France         | GSTM1 null | 1184 | 53.4% |
| Garte et al. (2001) | Germany        | GSTM1 null | 734 | 51.6% |
| Garte et al. (2001) | Italy          | GSTM1 null | 810 | 49.4% |
| Garte et al. (2001) | Spain          | GSTM1 null | 192 | 49.4% |
| Garte et al. (2001) | Sweden         | GSTM1 null | 544 | 55.9% |
| Garte et al. (2001) | United Kingdom | GSTM1 null | 1112 | 57.8% |
| Garte et al. (2001) | Netherlands    | GSTM1 null | 419 | 50.4% |
| Garte et al. (2001) | Norway         | GSTM1 null | 423 | 50.6% |
| Garte et al. (2001) | Portugal       | GSTM1 null | 501 | 58.3% |
| Garte et al. (2001) | United States  | GSTM1 null | 1751 | 54.3% |
| Garte et al. (2001) | Saudi Arabia   | GSTM1 null | 895 | 56.3% |
| Garte et al. (2001) | Canada         | GSTM1 null | 304 | 51.3% |
| Garte et al. (2001) | Singapore      | GSTM1 null | 244 | 56.2% |
| Garte et al. (2001) | Korea          | GSTM1 null | 165 | 52.1% |
| Studies of Turkey (see Table 3) | Turkey | GSTM1 null | 1809 | 41.2% |
Competing interests
The author(s) declare that they have no competing interests.

References
1. National Cancer Institute: SEER Cancer Statistics Review. Bethesda, MD: National Institutes of Health; 2001:1973–1998.
2. Perera FP: Molecular epidemiology of environmental carcinogenesis. Recent Results Cancer Res 1998, 154:39-46.
3. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility. Gene 1995, 159:13-21.
4. Strogn LC, Amos CI: Inherited susceptibility. In Cancer Epidemiology and Prevention Edited by: Schottenfeld D, Searle JG, Fraumeni JF. Oxford University Press, New York; 1996:559-582.
5. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Burkiewicz D, Cascorbi I, Clapper ML, Doltzan V, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Kalina I, Kremers P, Le Marchand L, London S, Rannug A, Romkes M, Schoket B, Seidegard J, Strange RC, Stucker I, To-Figueras J, Garte S: Polymorphisms in CYPIA1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003, 32:60-3.
6. Hayes JD, Pulford DJ: The glutathione S-transferase superfene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600.
7. Ads M, Demir I, Aytın S, Koskal V, Cetinelik U, Dincer Ş: GSTM1 Gene Polymorphisms on Lung Cancer Development in the Turkish Population. Turkish Respiratory Journal 2005, 6(1):131-134.
8. Garte S, Gaspari L, Alexandre AK, Ambrosone C, Aturup H, Aturup JL, Baranova J, Bathun L, Benhamou S, Boffetta P, Bouchard C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell’Orco M, Doltzan V, Dreisler CM, Fryer A, Haugen A, Hahn DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Khâa M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EMM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parli FF, Pastorello R, Persson I, Peters WVH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Sticker I, Sugimura H, To-Figueras J, Vineis J, Yu MC, Taioli E: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10(12):129-134.
9. Ada AO, Suzen SH, Iscan M: Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population. Toxicol Lett 2004, 151:31-35.
10. Quinones L, Berthou F, Varela N, Peters WHM, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Sticker I, Sugimura H, To-Figueras J, Vineis J, Yu MC, Taioli E: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10(12):129-134.
11. Houstoun RS: Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 1999, 8:675-82.
12. Benhamou S, Lee WJ, Alexandre AK, Boffetta P, Bouchard C, Burkiewicz D, Brockmoller J, Clapper ML, Daly A, Doltzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Khâa M, Kremers P, Le Marchand L, London S, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields PG, Strange RC, Stucker I, To-Figueras J, Brennan P, Taioli E: Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002, 23:1343-50.
13. Hung RJ, Boffetta P, Brockmoller J, Burkiewicz D, Cascorbi I, Clapper ML, Garte S, Haugen A, Hirvonen A, Anttila S, Kalina I, Le Marchand L, London S, Rannug A, Romkes M, Salagovic J, Schoket B, Gaspari L, Taioli E: CYPIA1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003, 24:875-82.
14. Teixeira JP, Gaspar J, Martinho G, Silva S, Rodrigues S, Mayan O, Martin E, Farmer PB, Rueff J: Aromatic DNA adduct levels in coke oven workers: correlation with polymorphisms in genes GSTPI, GSTM1, GSTT1 and CYPIA1. Mutat Res 2002, 517:147-55.
15. Wang J, Deng Y, Cheng J, Ding J, Tokudome S: GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. Cancer Lett 2003, 201:185-93.
16. Jourenkova-Mironova N, Wikman H, Bouchard C, Vaho A, Dayer P, Benhamou S, Hirvonen A: Role of glutathione S-transferase GSTM1, GSTT1, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenet 1998, 8:495-502.
17. Hayes JD, Strange RC: Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000, 60(6):445-66.
18. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lue AF: Associations of CYPIA1, GSTM1, and CYPI2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998, 58:4658-63.
19. Adachi S, Watanabe J, Kawajiri K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P450AIa and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1995, 86(8):866-870.
20. Kihara M, Noda K, Kihara M: Distribution of GSTM1 null genotype in relation to gender, age, and smoking status in Japanese lung cancer patients. Pharmacogenetics 1995, 5 Spec5:S47-54.
21. Lan Q, He X, Costa DJ, Tian L, Rothman N, Hu G, Mumford JL: Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: a case-control study in Xuan Wei, China. Cancer Epidemiol Biomarkers Prev 2000, 9:605-8.
22. Sun GF, Shimojo N, Pi JB, Lee S, Kumagai Y: Gene deficiency of glutathione S-transferase mu isoform associated with susceptibility to lung cancer in a Chinese population. Cancer Lett 1997, 113:169-72.
23. Woodson K, Stewart C, Barrett M, Bhat NK, Vartamo J, Taylor PR, Albanes D: Effect of vitamin intake on the relationship between GSTM1, smoking, and lung cancer risk among smokers. Cancer Epidemiol Biomarkers Prev 1999, 9:695-70.
24. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD: Glutathione S-transferase M1 deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995, 4(6):589-594.
25. Errico A, Taioli E, Chen X, Vineis P: Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996, 1:149-73.
26. Pinarhs K, Silig Y, Cetinkaya O, Seyifikli Z, Pinarhs E: Strong association between the GSTM1 null genotype and lung cancer in a Turkish population. Cancer Genet Cytofegenet 2003, 146(1):125-129.
27. Aras S: An Investigation on the frequency of GSTM1 gene in Turkish population by RFLP: A Correlation between null allele gene frequency and lung cancer. Ankara Universitesi Tes 2001, 1:1-14.
28. Ozturk O, Iibir T, Yaylim I, Kocaturk CI, Gurses A: GSTM1 gene polymorphism and daily fruit consumption in Turkish patients with non-small cell lung carcinomas. In Vivo 2003, 17:625-32.
29. Hong YS, Chang JH, Kwon OJ, Ham YA, Choi JH: Polymorphism of the CYPIA1 and glutathione-S-transferase gene in Korean lung cancer patients. Exp Mol Med 1998, 30:192-8.
30. Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingelman-Sundberg M: Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 1999, 81(3):322-9.
31. Kelsey TK, Spitz MR, Zheng-Fa Z, Wienczek JC: Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minutepopulations (Texas, United States). Cancer Causes Control 1997, 8:254-9.
32. Ozbek U, Aydın M, Hatýrnaz O, Metabolizing Enzyme Polymorphism (GSTM1, GSTT1, CYPIA1, CYPD2) and Their Association as a Potential Susceptibility to Pediatric ALL. American Society of Hematology 43rd Annual Meeting and Exposition Orlando, December 7–11, FL 2001.
33. Seyitoglu A, Hatýrnaz O, Ozbek U: Detoksifikasyon Enzim Gen Polimorfizmlerinin Akut Lüsemeyi Etiyolojisiolosideki Rolleri. Turkish Society of Hematology 30th Annual Meeting, October 10–14, 2003, ISTANBUL.
34. Aktas D, Ozen H, Atsu N, Tekin A, Sozen S, Tuncbilek E: Glutathione S-transferase M1 gene polymorphism in bladder cancer patients. A marker for invasive bladder cancer? Cancer Genet Cytogenet 2001, 125:1-4.

35. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, Tez M, Cetinkaya M, Ozcok T: Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 2001, 75:459-64.

36. Tamer L, Calikoglu M, Ates NA, Yildirim H, Ercan B, Saritas E, Unlu A, Atik U: Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respiratory 2004, 9:493-8.

37. Tursen U, Tamer L, Eskandari G, Kaya TI, Ates NA, Ikioglu G, Atik U: Glutathione S-transferase polymorphisms in patients with Behcet's disease. Arch Dermatol Res 2004, 296:185-7.

38. Tamer L, Ercan B, Camsari A, Yildirim H, Cicik D, Sucu N, Aces NA, Atik U: Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease. Basic Res Cardiol 2004, 99:223-9.